Internal Medicine, Medical Oncology · Philadelphia, PA
NPI
1144243858
Since 2006
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
333 Cottman Ave
Philadelphia, PA, 19111
Phone (215) 728-2500
Groups this clinician bills Medicare through
Medicare paid, 2024
$20K
219 services
Medicare patients, 2024
118
Average age 74
Drug cost, 2024
$2.8M
484 prescriptions
Company payments, 2025
$547
From 5 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Margaret Von-Mehren was code 99214 (office e&m - established), 90 times for 61 patients. In total Margaret Von-Mehren billed 219 services in 11 codes, and Medicare paid $20K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-08-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 90 | 61 | $71.97 | $6,477 |
| 99215 Office E&M - Established | Facility | 51 | 32 | $108.58 | $5,537 |
| 99213 Office E&M - Established | Facility | 18 | 15 | $53.41 | $961 |
| 99214 Office E&M - Established | Office | 16 | 12 | $105.40 | $1,686 |
| 99204 Office E&M - New | Facility | 15 | 15 | $104.98 | $1,575 |
| 99205 Office E&M - New | Facility | 11 | 11 | $147.35 | $1,621 |
By year: 2022 $29K for 328 services; 2023 $27K for 306 services; 2024 $20K for 219 services.
Medicare prescription drug claims, 2024
In 2024, the drug Margaret Von-Mehren prescribed most often to Medicare patients was Imatinib Mesylate, with 183 prescriptions and refills. In total Margaret Von-Mehren wrote 484 Medicare prescriptions that cost $2.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Imatinib Mesylate Generic | 183 | 185 | 20 | $283K |
| Gleevec Imatinib Mesylate | 57 | 57 | Under 11 | $615K |
| Qinlock Ripretinib | 19 | 19 | Under 11 | $770K |
| Ayvakit Avapritinib | 14 | 14 | Under 11 | $514K |
| Votrient Pazopanib Hcl | 14 | 14 | Under 11 | $182K |
| Eliquis Apixaban | 13 | 13 | Under 11 | $7,691 |
| Sunitinib Malate Generic | 13 | 13 | Under 11 | $65K |
| Zolpidem Tartrate Generic | 12 | 12 | Under 11 | $14.14 |
| Ondansetron Hcl Generic | 11 | 11 | Under 11 | $63.03 |
Brand drugs: 155 claims; generic drugs: 329 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Margaret Von-Mehren $547 ($107 in general payments such as food, travel and fees and $440 for research) from 5 companies. The largest payer was GlaxoSmithKline, LLC. with $490.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.